ADAPY (Adaptimmune Therapeutics) Ending Cash Position: $27.78 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Ending Cash Position?

Adaptimmune Therapeutics ADAPY +5.80% Ending Cash Position is $27.78 Mil as of Jun. 2025.

Adaptimmune Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2025 was $27.78 Mil.

Adaptimmune Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 ($93.21 Mil) to Mar. 2025 ($43.00 Mil) and declined from Mar. 2025 ($43.00 Mil) to Jun. 2025 ($27.78 Mil).

Adaptimmune Therapeutics's annual Ending Cash Position increased from Dec. 2022 ($109.60 Mil) to Dec. 2023 ($147.02 Mil) but then declined from Dec. 2023 ($147.02 Mil) to Dec. 2024 ($93.21 Mil).

Adaptimmune Therapeutics Ending Cash Position Related Terms

Adaptimmune Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Ending Cash Position Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.48 151.67 109.60 147.02 93.21

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 214.68 119.42 93.21 43.00 27.78

Adaptimmune Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Adaptimmune Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=147.017+-53.811
=93.21

Adaptimmune Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=43.004+-15.226
=27.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $27.78 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Ending Cash Position of $27.78 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Ending Cash Position too high?
Adaptimmune Therapeutics' current Ending Cash Position is $27.78 Mil.
How does Adaptimmune Therapeutics' Ending Cash Position compare to BCLI and APRE?
Adaptimmune Therapeutics' Ending Cash Position of $27.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Ending Cash Position is $27.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Ending Cash Position of $27.78 Mil. The current Ending Cash Position is $27.78 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Ending Cash Position is $27.78 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].